Delivery Order SPE2DB22D1017-SPE2DB23FG4DY
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of Amerisourcebergen Corporation, for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML pharmaceutical product. The $33,745.79 firm fixed price contract has an ultimate completion date of April 18, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued up to $999,999,999.00...
- This federal contract award is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $4,646.17 firm fixed-price contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on July 7, 2022, with a completion date of July 8, 2022. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical to...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,540.37, is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty pharmaceutical product. This is a delivery order contract, with a firm fixed-price pricing type, and an ultimate completion date of December 18, 2024. The contract does not have a set-aside designation, indicating open...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,437.19, is a Firm Fixed Price Delivery Order for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML. The contract has an ultimate completion date of February 12, 2025 and was awarded on February 11, 2025. This contract award is part of a larger Indefinite Delivery Contract (IDC) valued at...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML. The firm-fixed-price delivery order, valued at $17,065.51, has an ultimate completion date of August 22, 2024. This award is not associated with a set-aside program. Amerisourcebergen Drug Corp's Corporate Office division holds this contract, which is a child contract under a larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $10,542.44 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp for the supply of Rebif 44 mcg/0.5 ml syringes. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which enables efficient procurement of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $25,198.89, is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty pharmaceutical product. The contract has a firm fixed price and is set to expire on June 3, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the...
- This federal contract award is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, which has a value of $16,757.61, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on April 6, 2023. The contract has an ultimate completion date of April 7, 2023 and is a Firm Fixed Price Delivery Order. Amerisourcebergen Drug Corp is a for-profit organization that is...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML. The contract has a ceiling value of $8,202.62 and is a firm fixed price delivery order that runs through August 2024. No set-aside designation was used. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through...
- This federal contract award is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML pharmaceuticals to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $9,980.49, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a delivery order with a firm fixed price and has an ultimate completion date of October 25, 2023. This award is not a set-aside contract. Amerisourcebergen Drug Corp...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB23FG4DYDelivery Order
The federal contract award, issued by the Defense Logistics Agency (DLA), is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML pharmaceutical products. The $11,566.64 firm fixed-price contract has a completion date of September 29, 2023 and was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. This contract is a delivery order under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. This award demonstrates Amerisourcebergen's extensive experience and capabilities in supplying essential medical commodities, including specialty medications, to federal government agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 9/28/23 |